Treatment of Jak2 inhibitor AZD1480 suppresses PCa xenograft tumor development, and prolongs survival time of tumor-bearing mice as compared with vehicle or docetaxel-treated groups [121]. The gene discussed is JAK2; the disease is neoplasm.